ARMATA PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $10.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2026-06-30 was -$91.02M, a 1682.65% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2026-03-31 was $101.06M.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-09-30 was $14.64M.
- ARMATA PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2025-06-30 was $5.75M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2026-06-30 | -$91.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $10.04M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $101.06M 10-Q · filed 2026-05-13 | ||
| 2025-09-30 | $14.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $20.39M derived: sum of 2 quarters · filed 2026-08-12 | $15.19M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $5.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $548.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | -$5.20M 10-Q · filed 2026-05-13 | ||
| 2024-09-30 | -$6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$17.28M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$10.37M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |